Valvular Cardiomyopathy in Aortic Valve Regurgitation Correlates with Myocardial Fibrosis
Abstract
:1. Introduction
2. Methods
2.1. Ethical Statement
2.2. Surgical Intervention
2.3. Histology
2.4. In Vitro Contractility
2.5. Statistical Analysis
3. Results
3.1. Study Population
3.2. Myocardial Fibrosis
3.3. In Vitro Contractility and Myocardial Fibrosis
4. Discussion
4.1. Clinical Perspective
4.2. Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Vahanian, A.; Beyersdorf, F.; Praz, F.; Milojevic, M.; Baldus, S.; Bauersachs, J.; Capodanno, D.; Conradi, L.; De Bonis, M.; De Paulis, R.; et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. Heart J. 2021, 43, 561–632. [Google Scholar] [CrossRef] [PubMed]
- Borer, J.S.; Truter, S.L.; Gupta, A.; Herrold, E.M.; Carter, J.N.; Lee, E.; Pitlor, L. Heart failure in aortic regurgitation: The role of primary fibrosis and its cellular and molecular pathophysiology. Adv. Cardiol. 2004, 41, 16–24. [Google Scholar] [PubMed]
- Petersen, J.; Neumann, N.; Naito, S.; Gross, T.S.; Massel, R.; Reichenspurner, H.; Girdauskas, E. Persistence of Reduced Left Ventricular Function after Aortic Valve Surgery for Aortic Valve Regurgitation: Bicuspid versus Tricuspid. Thorac. Cardiovasc. Surg. 2021, 69, 389–395. [Google Scholar] [CrossRef] [PubMed]
- Petersen, J.; Kloth, B.; Iqbal, S.; Reichenspurner, H.; Geelhoed, B.; Schnabel, R.; Eschenhagen, T.; Christ, T.; Girdauskas, E. Blunted beta-adrenoceptor-mediated inotropy in valvular cardiomyopathy: Another piece of the puzzle in human aortic valve disease. Eur. J. Cardio-Thorac. Surg. 2021, 60, 56–63. [Google Scholar] [CrossRef] [PubMed]
- Liu, S.K.; Magid, N.R.; Fox, P.R.; Goldfine, S.M.; Borer, J.S. Fibrosis, myocyte degeneration and heart failure in chronic experimental aortic regurgitation. Cardiology 1998, 90, 101–109. [Google Scholar] [CrossRef] [PubMed]
- Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef] [PubMed]
- Tarasoutchi, F.; Grinberg, M.; Spina, G.S.; Sampaio, R.O.; Cardoso, L.U.F.; Rossi, E.G.; Pomerantzeff, P.; Laurindo, F.; da Luz, P.L.; Ramires, J.A.F.; et al. Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology. J. Am. Coll. Cardiol. 2003, 41, 1316–1324. [Google Scholar] [CrossRef] [PubMed]
- Borer, J.S.; Hochreiter, C.; Herrold, E.M.; Supino, P.; Aschermann, M.; Wencker, D.; Devereux, R.B.; Roman, M.J.; Szulc, M.; Kligfield, P.; et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 1998, 97, 525–534. [Google Scholar] [CrossRef] [PubMed]
- Krayenbuehl, H.P.; Hess, O.M.; Schneider, J.; Turina, M. Left ventricular function and myocardial structure in aortic valve disease before and after surgery. Herz 1984, 9, 270–278. [Google Scholar] [PubMed]
- Azevedo, C.F.; Nigri, M.; Higuchi, M.L.; Pomerantzeff, P.M.; Spina, G.S.; Sampaio, R.O.; Tarasoutchi, F.; Grinberg, M.; Rochitte, C.E. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J. Am. Coll. Cardiol. 2010, 56, 278–287. [Google Scholar] [CrossRef] [PubMed]
- Everett, R.J.; Treibel, T.A.; Fukui, M.; Lee, H.; Rigolli, M.; Singh, A.; Bijsterveld, P.; Tastet, L.; Musa, T.A.; Dobson, L.; et al. Extracellular Myocardial Volume in Patients With Aortic Stenosis. J. Am. Coll. Cardiol. 2020, 75, 304–316. [Google Scholar] [CrossRef] [PubMed]
- Weidemann, F.; Herrmann, S.; Störk, S.; Niemann, M.; Frantz, S.; Lange, V.; Beer, M.; Gattenlöhner, S.; Voelker, W.; Ertl, G.; et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009, 120, 577–584. [Google Scholar] [CrossRef] [PubMed]
- Everett, R.J.; Tastet, L.; Clavel, M.A.; Chin, C.W.; Capoulade, R.; Vassiliou, V.S.; Kwiecinski, J.; Gomez, M.; van Beek, E.J.; White, A.C.; et al. Progression of Hypertrophy and Myocardial Fibrosis in Aortic Stenosis: A Multicenter Cardiac Magnetic Resonance Study. Circ. Cardiovasc. Imaging 2018, 11, e007451. [Google Scholar] [CrossRef] [PubMed]
- Baumgartner, H.; Iung, B.; Otto, C.M. Timing of intervention in asymptomatic patients with valvular heart disease. Eur. Heart J. 2020, 41, 4349–4356. [Google Scholar] [CrossRef]
- Elias, N.; Tarasoutchi, F.; Spina, G.S.; Sampaio, R.O.; Pomerantzeff, P.; Laurindo, F.R.; Grinberg, M. Myocardial fibrosis and ventricular remodeling in severe chronic aortic regurgitation. Arq. Bras. De Cardiol. 2009, 92, 63–67. [Google Scholar]
- Taniguchi, K.; Kawamaoto, T.; Kuki, S.; Masai, T.; Mitsuno, M.; Nakano, S.; Kawashima, Y.; Matsuda, H. Left ventricular myocardial remodeling and contractile state in chronic aortic regurgitation. Clin. Cardiol. 2000, 23, 608–614. [Google Scholar] [CrossRef] [PubMed]
- Malahfji, M.; Senapati, A.; Tayal, B.; Nguyen, D.T.; Graviss, E.A.; Nagueh, S.F.; Reardon, M.J.; Quinones, M.; Zoghbi, W.A.; Shah, D.J. Myocardial Scar and Mortality in Chronic Aortic Regurgitation. J. Am. Heart Assoc. 2020, 9, e018731. [Google Scholar] [CrossRef] [PubMed]
- Prior, D.L.; Somaratne, J.B.; Jenkins, A.J.; Yii, M.; Newcomb, A.E.; Schalkwijk, C.G.; Black, M.J.; Kelly, D.J.; Campbell, D.J. Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery. Open Heart 2015, 2, e000278. [Google Scholar] [CrossRef] [PubMed]
- Zegard, A.; Okafor, O.; De Bono, J.; Kalla, M.; Lencioni, M.; Marshall, H.; Hudsmith, L.; Qiu, T.; Steeds, R.; Stegemann, B.; et al. Myocardial Fibrosis as a Predictor of Sudden Death in Patients With Coronary Artery Disease. J. Am. Coll. Cardiol. 2021, 77, 29–41. [Google Scholar] [CrossRef] [PubMed]
- Mentias, A.; Feng, K.; Alashi, A.; Rodriguez, L.L.; Gillinov, A.M.; Johnston, D.R.; Sabik, J.F.; Svensson, L.G.; Grimm, R.A.; Griffin, B.P.; et al. Long-Term Outcomes in Patients With Aortic Regurgitation and Preserved Left Ventricular Ejection Fraction. J. Am. Coll. Cardiol. 2016, 68, 2144–2153. [Google Scholar] [CrossRef] [PubMed]
Aortic Stenosis (AS) (n = 41) | Aortic Regurgitation (AR) (n = 51) | p-Value | |
---|---|---|---|
Age (years) | 58.7 ± 17.0 | 53.3 ± 15.3 | 0.116 |
Male | 16 (39.0%) | 41 (80.4%) | <0.001 |
Body mass index (kg/m2) | 28.2 ± 5.0 | 26.0 ± 3.9 | 0.022 |
Arterial hypertension | 21 (51.1%) | 20 (46.0%) | 0.540 |
Dyslipidemia | 11 (27.5%) | 11 (22.0%) | 0.546 |
Coronary artery disease | 10 (25.0%) | 6 (12.0%) | 0.109 |
Diabetes mellitus | 5 (12.2%) | 1 (1.9%) | 0.103 |
Chronic kidney disease (GFR < 60 mL/min) | 1 (2.4%) | 3 (5.9%) | 0.199 |
Atrial fibrillation | 3 (7.3%) | 4 (7.8%) | 0.462 |
NYHA | 0.002 | ||
- Class II | 13 (32.5%) | 19 (37.3%) | |
- Class III | 17 (42.4%) | 4 (7.8%) | |
- Class IV | 0 | 2 (3.9%) | |
Left ventricular (LV) ejection fraction (%) | 60.5 ± 7.1 | 52.5 ± 9.9 | <0.001 |
LV end-diastolic diameter (mm) | 39.7 ± 21.2 | 59.4 ± 15.6 | <0.001 |
Aortic valve morphology | 0.007 | ||
- Tricuspid | 20 (48.8%) | 21 (41.2%) | |
- Bicuspid | 12 (29.3%) | 28 (54.9%) | |
- Unicuspid | 9 (22.0%) | 2 (3.9%) | |
Preoperative pro-BNP value (pg/mL) | 860.6 (39–3696) | 1045.1 (24–9334) | 0.646 |
Medication with Betablocker | 11 (27.5%) | 20 (40.0%) | 0.215 |
Aortic Stenosis (AS) (n = 41) | Aortic Regurgitation (AR) (n = 51) | p-Value | |
---|---|---|---|
Medication with Betablocker | 11 (27.5%) | 20 (40.0%) | 0.215 |
ACE inhibitor | 14 (34.1%) | 24 (47.0%) | 0.102 |
AT-II receptor blocker | 6 (14.6%) | 8 (15.6%) | 0.978 |
Ca-channel blocker | 12 (29.2%) | 7 (13.7%) | 0.107 |
Statin | 9 (21.9%) | 8 (15.6%) | 0.482 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Petersen, J.; Iqbal, S.; Gedeon, N.; Kloth, B.; Pecha, S.; Yildirim, Y.; Eschenhagen, T.; Reichenspurner, H.; Christ, T.; Girdauskas, E. Valvular Cardiomyopathy in Aortic Valve Regurgitation Correlates with Myocardial Fibrosis. J. Clin. Med. 2023, 12, 2915. https://doi.org/10.3390/jcm12082915
Petersen J, Iqbal S, Gedeon N, Kloth B, Pecha S, Yildirim Y, Eschenhagen T, Reichenspurner H, Christ T, Girdauskas E. Valvular Cardiomyopathy in Aortic Valve Regurgitation Correlates with Myocardial Fibrosis. Journal of Clinical Medicine. 2023; 12(8):2915. https://doi.org/10.3390/jcm12082915
Chicago/Turabian StylePetersen, Johannes, Shahria Iqbal, Naomi Gedeon, Benjamin Kloth, Simon Pecha, Yalin Yildirim, Thomas Eschenhagen, Hermann Reichenspurner, Torsten Christ, and Evaldas Girdauskas. 2023. "Valvular Cardiomyopathy in Aortic Valve Regurgitation Correlates with Myocardial Fibrosis" Journal of Clinical Medicine 12, no. 8: 2915. https://doi.org/10.3390/jcm12082915
APA StylePetersen, J., Iqbal, S., Gedeon, N., Kloth, B., Pecha, S., Yildirim, Y., Eschenhagen, T., Reichenspurner, H., Christ, T., & Girdauskas, E. (2023). Valvular Cardiomyopathy in Aortic Valve Regurgitation Correlates with Myocardial Fibrosis. Journal of Clinical Medicine, 12(8), 2915. https://doi.org/10.3390/jcm12082915